Aligos Therapeutics
Quarterly Financials
| Values in thousands | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
Revenue | $311 | $629 | $1,269 | $1,061 |
Gross Profit | 311 | -42 | 1,269 | 451 |
EBITDA | -18,733 | -19,892 | -19,464 | -26,414 |
EBIT | -19,243 | -20,563 | -20,131 | -27,024 |
Net Income | 43,088 | -82,150 | -19,259 | 5,061 |
Net Change In Cash | 311 | 629 | 1,269 | 1,061 |
Free Cash Flow | -20,952 | -18,431 | -20,127 | -19,500 |
Cash | 73,763 | 36,997 | 35,331 | 45,148 |
Basic Shares | 8,709 | 6,282 | 6,272 | 3,092 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $3,945 | $15,529 | $13,907 | $4,359 |
Gross Profit | 1,323 | 12,460 | 13,907 | 4,359 |
EBITDA | -89,154 | -85,058 | -93,905 | -124,543 |
EBIT | -88,127 | -97,580 | -128,321 | |
Net Income | -131,211 | -87,679 | -96,046 | -128,332 |
Net Change In Cash | 3,945 | 15,529 | 13,907 | 4,359 |
Cost of Revenue | -105,518 | -33,963 | ||
Free Cash Flow | -80,873 | -79,016 | -80,332 | -116,554 |
Cash | 36,997 | 135,704 | 81,347 | 186,816 |
Basic Shares | 6,264 | 24,873 | 42,695 | 39,855 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-03-31 | -$2.11 |
2024-12-31 | -$13.10 |
2024-09-30 | -$3.07 |
2024-06-30 | $0.03 |
